Integrating New Standards for Metastatic HER2+ Breast Cancer
March 20th 2023
The first-line standard of care for patients with HER2-postive metastatic breast cancer has long been held by the combination of pertuzumab, trastuzumab, and a taxane established with the publication of data from the CLEOPATRA trial.